TDP–43 Seeding Mouse Models
Recapitulate the key structural features and spreading of TDP-43 proteinopathy found in the brain of ALS patients
Amyotrophic lateral sclerosis (ALS) exists on a continuum with frontotemporal dementia (FTD), which also affects the frontal and temporal lobes. It is increasingly recognized that the spreading of TDP-43 plays a key role in the pathophysiology of ALS and FTD.
Injection of brain extracts from these diseases in the brain of mice closely mimics the structural features of the TDP-43 aggregates found in patients and allows studying of TDP-43 spreading as a therapeutic readout.
InnoSer has extensive experience with seeding-based ALS mouse models, based on both recombinant and patient-derived seeds. Brain extracts from other FTD patients can also be used, mimicking the unique disease pathophysiology. The choice of the patient brain source depends on the disease of interest.
Take advantage of InnoSer’s preclinical contract research expertise in modelling TDP-43 pathology, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience working with seeding-based ALS, but also other neurodegenerative disease models. We are happy to help guide your decision on study design fit for your current research goals.
TDP–43 Seeding Mouse Model key model characteristics:
- Recombinant and patient-derived TDP-43 brain extract seeds are available.
- TDP-43 aggregates can be injected in both wild-type (WT) or transgenic mice.
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Test the efficacy of your treatments in the following battery of behavioural tests:
- Immunohistochemistry (TDP-43 accumulation, neuroinflammation)
- Immunofluorescence and FISH
Related ALS Disease model options
Neurology Platform Overview
Transgenic SOD1 Models
Transgenic TDP-43 Models
InnoSer offers several transgenic TDP-43 mouse models that recapitulate key structural features and spreading of TDP-43 proteinopathy.
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know